- Published on
Emergency And Acute Medicine – Pulmonary Edema
Pulmonary edema is the accumulation of fluid within the interstitium and alveoli due to imbalance in Starling forces, resulting in leakage of fluid from pulmonary capillaries. It is broadly categorized as cardiogenic or noncardiogenic. Cardiogenic pulmonary edema results from abnormal cardiac function leading to inadequate forward flow and elevated hydrostatic pressures, often seen in acute decompensated heart failure (AHF). Noncardiogenic pulmonary edema results from increased alveolar–capillary membrane permeability without primary cardiac dysfunction and includes acute lung injury and acute respiratory distress syndrome (ARDS), defined by a PaO₂/FiO₂ ratio ≤200 mm Hg.
Heart failure affects approximately 5.8 million people in the United States and increases with age, affecting about 10% of individuals over 75 years old. Thirty to forty percent of patients with heart failure are hospitalized annually, with an 11% one-month mortality following admission for acute heart failure.
Cardiogenic causes include systolic dysfunction (ischemic heart disease, cardiomyopathy, myocarditis), pressure overload (aortic stenosis, systemic hypertension), volume overload (mitral or aortic regurgitation), diastolic dysfunction (mitral stenosis, hypertrophic cardiomyopathy), and high-output states such as anemia, hyperthyroidism, arteriovenous fistula, or wet beriberi. Noncardiogenic causes include sepsis, aspiration, inhalation injury, near drowning, disseminated intravascular coagulation, pancreatitis, pulmonary contusion, severe trauma, uremia, high-altitude pulmonary edema, neurogenic pulmonary edema, drug overdose (e.g., narcotics, salicylates), pulmonary embolism, fat embolism, and transfusion-related acute lung injury.
Patients typically present with progressive dyspnea, initially on exertion and later at rest. Orthopnea, paroxysmal nocturnal dyspnea, peripheral edema, cough, weakness, and acute weight gain are common in cardiogenic causes. Physical examination may reveal tachypnea, hypoxia, diaphoresis, cyanosis, jugular venous distention, rales, wheezing, S3 or S4 gallop, tachycardia, and peripheral edema. Patients may be hypertensive or hypotensive. Noncardiogenic edema produces similar pulmonary findings but usually lacks peripheral signs of volume overload.
Evaluation includes ECG to assess for ischemia or dysrhythmias and chest radiography to confirm diagnosis and evaluate severity. Laboratory studies typically include BNP or NT-proBNP, cardiac troponins, renal function, and electrolytes. BNP <100 pg />L makes heart failure unlikely, whereas >500 pg/mL strongly suggests cardiogenic pulmonary edema. Values between 100–500 pg/mL are indeterminate. BNP may be falsely elevated in renal failure and may not rise immediately in very acute heart failure. Troponin elevation occurs in about 20% of AHF cases and carries negative prognostic implications. Hyponatremia and elevated creatinine indicate severe disease and worse prognosis.
Chest radiography in cardiogenic edema may demonstrate cardiomegaly, cephalization of pulmonary vessels, Kerley B lines, pleural effusions, and bilateral perihilar “butterfly” alveolar edema. In noncardiogenic edema, bilateral infiltrates are present without cardiomegaly. Radiographs may be normal early in the disease. Bedside ultrasonography can reveal bilateral B-lines (comet-tail artifacts), supporting the diagnosis. Echocardiography evaluates ventricular function and structural abnormalities.
Differential diagnoses include COPD exacerbation, asthma, pneumonia, pulmonary embolism, pneumothorax, pleural effusion, pericardial tamponade, anaphylaxis, metabolic acidosis, and hyperventilation syndrome.
Management begins with airway, breathing, and circulation assessment. Prehospital care includes oxygen via nonrebreather mask, IV access, cardiac monitoring, pulse oximetry, and sublingual nitrates if blood pressure permits. In severe cases, positive-pressure ventilation or intubation may be required.
In the emergency department, the patient should be positioned upright. Supplemental oxygen and close monitoring are essential. Noninvasive ventilation (CPAP or BiPAP) improves oxygenation, reduces work of breathing, decreases left ventricular afterload, and reduces intubation rates and mortality in AHF. CPAP and BiPAP are similarly effective. In noncardiogenic edema and ARDS, low tidal volume ventilation (6 mL/kg) with adequate positive end-expiratory pressure (PEEP) is recommended.
Treatment differs by hemodynamic status. Normotensive or hypertensive patients benefit from nitrates (sublingual or IV nitroglycerin; nitroprusside in select cases) to reduce preload and afterload. Diuretics such as furosemide or bumetanide are typically administered after initial stabilization. ACE inhibitors may also be considered. Hypotensive patients with evidence of end-organ hypoperfusion require inotropic or vasopressor support, such as dobutamine, dopamine, norepinephrine, or milrinone, and should avoid nitrates and aggressive vasodilators. Unstable atrial fibrillation may require direct cardioversion. Noncardiogenic edema requires treatment of the underlying cause.
Medications commonly used include nitroglycerin (SL or IV), furosemide 20–80 mg IV, bumetanide 1–3 mg IV, dobutamine infusion, dopamine infusion, norepinephrine infusion, milrinone, and ACE inhibitors such as captopril or enalapril. Aspirin should be administered if myocardial infarction is suspected.
Most patients with pulmonary edema require hospital admission. ICU admission is indicated for those requiring positive-pressure ventilation, inotropic support, ARDS management, or treatment of acute myocardial infarction. Patients with new-onset pulmonary edema, ECG changes, advanced age, renal dysfunction, hypotension, digoxin use, or anemia should be admitted to a monitored unit. Discharge may be considered only in select low-risk patients with mild disease that resolves completely in the ED and reliable follow-up.
Nitrates are first-line therapy in normotensive or hypertensive cardiogenic pulmonary edema to reduce preload. BNP is useful in differentiating AHF from other causes of dyspnea. Chest radiographic findings may be absent early in the course. Early aggressive treatment with nitrates, diuretics, and noninvasive ventilation can rapidly improve outcomes and reduce mortality.
Pulmonary edema is the accumulation of fluid within the interstitium and alveoli due to imbalance in Starling forces, resulting in leakage of fluid from pulmonary capillaries. It is broadly categorized as cardiogenic or noncardiogenic. Cardiogenic pulmonary edema results from abnormal cardiac function leading to inadequate forward flow and elevated hydrostatic pressures, often seen in acute decompensated heart failure (AHF). Noncardiogenic pulmonary edema results from increased alveolar–capillary membrane permeability without primary cardiac dysfunction and includes acute lung injury and acute respiratory distress syndrome (ARDS), defined by a PaO₂/FiO₂ ratio ≤200 mm Hg.
Heart failure affects approximately 5.8 million people in the United States and increases with age, affecting about 10% of individuals over 75 years old. Thirty to forty percent of patients with heart failure are hospitalized annually, with an 11% one-month mortality following admission for acute heart failure.
Cardiogenic causes include systolic dysfunction (ischemic heart disease, cardiomyopathy, myocarditis), pressure overload (aortic stenosis, systemic hypertension), volume overload (mitral or aortic regurgitation), diastolic dysfunction (mitral stenosis, hypertrophic cardiomyopathy), and high-output states such as anemia, hyperthyroidism, arteriovenous fistula, or wet beriberi. Noncardiogenic causes include sepsis, aspiration, inhalation injury, near drowning, disseminated intravascular coagulation, pancreatitis, pulmonary contusion, severe trauma, uremia, high-altitude pulmonary edema, neurogenic pulmonary edema, drug overdose (e.g., narcotics, salicylates), pulmonary embolism, fat embolism, and transfusion-related acute lung injury.
Patients typically present with progressive dyspnea, initially on exertion and later at rest. Orthopnea, paroxysmal nocturnal dyspnea, peripheral edema, cough, weakness, and acute weight gain are common in cardiogenic causes. Physical examination may reveal tachypnea, hypoxia, diaphoresis, cyanosis, jugular venous distention, rales, wheezing, S3 or S4 gallop, tachycardia, and peripheral edema. Patients may be hypertensive or hypotensive. Noncardiogenic edema produces similar pulmonary findings but usually lacks peripheral signs of volume overload.
Evaluation includes ECG to assess for ischemia or dysrhythmias and chest radiography to confirm diagnosis and evaluate severity. Laboratory studies typically include BNP or NT-proBNP, cardiac troponins, renal function, and electrolytes. BNP <100 pg />L makes heart failure unlikely, whereas >500 pg/mL strongly suggests cardiogenic pulmonary edema. Values between 100–500 pg/mL are indeterminate. BNP may be falsely elevated in renal failure and may not rise immediately in very acute heart failure. Troponin elevation occurs in about 20% of AHF cases and carries negative prognostic implications. Hyponatremia and elevated creatinine indicate severe disease and worse prognosis.
Chest radiography in cardiogenic edema may demonstrate cardiomegaly, cephalization of pulmonary vessels, Kerley B lines, pleural effusions, and bilateral perihilar “butterfly” alveolar edema. In noncardiogenic edema, bilateral infiltrates are present without cardiomegaly. Radiographs may be normal early in the disease. Bedside ultrasonography can reveal bilateral B-lines (comet-tail artifacts), supporting the diagnosis. Echocardiography evaluates ventricular function and structural abnormalities.
Differential diagnoses include COPD exacerbation, asthma, pneumonia, pulmonary embolism, pneumothorax, pleural effusion, pericardial tamponade, anaphylaxis, metabolic acidosis, and hyperventilation syndrome.
Management begins with airway, breathing, and circulation assessment. Prehospital care includes oxygen via nonrebreather mask, IV access, cardiac monitoring, pulse oximetry, and sublingual nitrates if blood pressure permits. In severe cases, positive-pressure ventilation or intubation may be required.
In the emergency department, the patient should be positioned upright. Supplemental oxygen and close monitoring are essential. Noninvasive ventilation (CPAP or BiPAP) improves oxygenation, reduces work of breathing, decreases left ventricular afterload, and reduces intubation rates and mortality in AHF. CPAP and BiPAP are similarly effective. In noncardiogenic edema and ARDS, low tidal volume ventilation (6 mL/kg) with adequate positive end-expiratory pressure (PEEP) is recommended.
Treatment differs by hemodynamic status. Normotensive or hypertensive patients benefit from nitrates (sublingual or IV nitroglycerin; nitroprusside in select cases) to reduce preload and afterload. Diuretics such as furosemide or bumetanide are typically administered after initial stabilization. ACE inhibitors may also be considered. Hypotensive patients with evidence of end-organ hypoperfusion require inotropic or vasopressor support, such as dobutamine, dopamine, norepinephrine, or milrinone, and should avoid nitrates and aggressive vasodilators. Unstable atrial fibrillation may require direct cardioversion. Noncardiogenic edema requires treatment of the underlying cause.
Medications commonly used include nitroglycerin (SL or IV), furosemide 20–80 mg IV, bumetanide 1–3 mg IV, dobutamine infusion, dopamine infusion, norepinephrine infusion, milrinone, and ACE inhibitors such as captopril or enalapril. Aspirin should be administered if myocardial infarction is suspected.
Most patients with pulmonary edema require hospital admission. ICU admission is indicated for those requiring positive-pressure ventilation, inotropic support, ARDS management, or treatment of acute myocardial infarction. Patients with new-onset pulmonary edema, ECG changes, advanced age, renal dysfunction, hypotension, digoxin use, or anemia should be admitted to a monitored unit. Discharge may be considered only in select low-risk patients with mild disease that resolves completely in the ED and reliable follow-up.
Nitrates are first-line therapy in normotensive or hypertensive cardiogenic pulmonary edema to reduce preload. BNP is useful in differentiating AHF from other causes of dyspnea. Chest radiographic findings may be absent early in the course. Early aggressive treatment with nitrates, diuretics, and noninvasive ventilation can rapidly improve outcomes and reduce mortality.
0 Comments
